In summary, the results presented in this report demonstrated that terrein inhibits LPS-induced endotoxemia in mice and decreased levels of IL-1β and IL-6 in serum and lungs were observed in terrein-treated mice. The gene discussed is IL6; the disease is serum lipopolysaccharide activity.